“Is Curing Patients a Sustainable Business Model?” Goldman Sachs Analysts Ask

Beth Mole

One-shot cures for diseases are not great for business—more specifically, they’re bad for longterm profits—Goldman Sachs analysts noted in an April 10 report for biotech clients …

The investment banks’ report, titled “The Genome Revolution,” asks clients the touchy question: “Is curing patients a sustainable business model?” The answer may be “no,” according to follow-up information provided.

… To get around the sustainability issue overall, the report suggests that biotech companies focus on diseases or conditions that seem to be becoming more common and/or are already high-incidence. It also suggests that companies be innovative and constantly expanding their portfolio of treatments. This can “offset the declining revenue trajectory of prior assets.” Lastly, it hints that, as such cures come to fruition, they could open up more investment opportunities in treatments for “disease of aging.”

Latest articles

Madhava Setty Primum non nocere, “first and foremost, I will do no...
Emily Kopp and Karolina Corin A team of Western virologists could face...
privacyisyourright.ca Using the declaration of a pandemic as an excuse, the CPSO...
Aric Cox Many of you have been on protocol, after protocol, after...
Jeffrey Jaxen Talking to the news host, German Health Minister Karl Lauterbach...
Merinda Teller Over the past six decades, solid organ transplantation has gone...

Thank you!

Thank you for your membership application. As soon as your payment has been received your membership will be activated and you will be informed via email.

Thank you.

Thank you!

The form has been submitted successfully!